SynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyReferences

View all Images (35)

Neurofibromatosis in Child
See also in: External and Internal Eye
Other Resources UpToDate PubMed

Neurofibromatosis in Child

See also in: External and Internal Eye
Contributors: David O'Connell MD, Andrew R. Blundell MSc, Elena B. Hawryluk MD, PhD, Belinda Tan MD, PhD, Susan Burgin MD
Other Resources UpToDate PubMed


The neurofibromatoses are a group of 3 disorders that manifest as tumors in both the central and peripheral nerve tissues. Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), while generally considered rare with respective incidences of 1 in 3000, 1 in 33 000, and 1 in 60 000 live births, respectively, are responsible for more tumors of the nervous system than all other neoplastic diseases.

While NF1 and NF2 are monogenetic diseases and are inherited in an autosomal dominant pattern with up to 50% de novo mutations, SWN has a less well-defined inheritance pattern, with new mutations ranging in excess of 50%. As a group, these 3 neurocutaneous conditions make up part of the rare tumor suppressor syndromes, and all interfere with tumor suppressor function at the genetic level. They do not exhibit any sex or ethnic predilections. Because they are clinically and pathophysiologically distinct, they are considered separately.

NF1, also known as von Recklinghausen disease, is a multisystem genetic disorder with hallmark cutaneous findings, including café au lait macules, neurofibromas, and axillary freckling. NF1 may affect the skin, nervous system, eyes, bone, and soft tissue. It is the most common autosomal dominant genetic disorder.

NF1 is often identified in childhood with the appearance of café au lait macules. The genetic defect is in a tumor suppressor gene on chromosome 17, which codes for neurofibromin, a RAS GTPase activating protein.

Diagnostic criteria for NF1:
The diagnosis of NF1 is made on clinical grounds based on 2 or more of the following features, if not better explained by an alternate diagnosis:
  • Six or more café au lait macules greater than 5 mm in diameter in prepubertal patients and greater than 15 mm in diameter in postpubertal patients
  • Two or more Lisch nodules (iris hamartomas)
  • An osseous lesion such as sphenoid dysplasia or thinning of a long bone's cortex, with or without pseudoarthrosis
  • At least 2 neurofibromas of any type or a single plexiform neurofibroma
  • Freckling in the axillary or inguinal region
  • Optic glioma (in early childhood)
  • A first-degree relative with NF1
Patients with NF1 are at increased risk of developing both benign and malignant neoplasms. Neurofibromas are seen in up to 60% of adult patients. Plexiform neurofibromas (present in 25% of patients) are a variant of neurofibroma that is typically deeper, more anatomically complex, and more likely to be symptomatic. Deep plexiform neurofibromas may degenerate into malignant peripheral nerve sheath tumors. In children, the most common NF1-associated malignancies are optic pathway gliomas (occurring in 10%-15% of all NF1 patients, usually by age 7) and other nonoptic glioma CNS tumors. Later in adolescence, patients are at increased risk of developing malignant peripheral nerve sheath tumors.

Other malignancies and tumors associated with NF1 include pheochromocytomas, meningiomas, sarcomas, gastrointestinal tumors of neuroendocrine origin (most commonly somatostatinoma, but gastrinomas, insulinomas, paragangliomas, and duodenal carcinoid tumors are also seen), and juvenile myelomonocytic leukemia (7-times increased risk compared to age-matched counterparts, and most commonly observed in NF1 patients who also have cutaneous juvenile xanthogranulomas). Children with NF1 have a 20-times greater risk, compared to the general population, of developing rhabdomyosarcomas, most commonly involving the bladder and prostate. In addition to tumors and skin findings, patients may also have learning disabilities (30%-50%), skeletal anomalies, vasculopathies (including heart disease), and endocrine abnormalities.

NF2, also known as bilateral acoustic neurofibromatosis and central neurofibromatosis, is an inherited autosomal dominant genetic disorder that is approximately 10 times less common than NF1. Patients with NF2 present primarily with vestibular schwannomas (schwannomas of the eighth cranial nerve), which are frequently bilateral. Hearing loss may be present. NF2 is associated with a different suppressor gene mutation than NF1. It is located on chromosome 22 and codes for a protein called merlin. Patients have fewer café au lait macules than those with NF1, and they do not form Lisch nodules in the iris.

Diagnostic criteria for NF2:
  • Bilateral vestibular schwannomas
  • A first-degree relative with NF2 in addition to either a unilateral vestibular schwannoma or any 2 of the following: meningioma, glioma, schwannoma, or juvenile posterior lenticular opacities
SWN is the least common of these 3 syndromes. SWN is more commonly sporadic in occurrence, but up to 25% are familially inherited in an autosomal dominant fashion. Individuals have nonintradermal schwannomas of the peripheral (90%) and spinal (75%) nerves and occasionally meningiomas (5%). While symptoms begin to develop in the teens or 20s, due to a typical diagnostic delay of approximately 10 years, most patients are not diagnosed until their third to fourth decades. Presenting symptoms are most often chronic pain (45%-50%), which is localized or diffuse and does not always correlate to the location of schwannomas, or an asymptomatic mass lesion (27%). Pigmentary changes and cutaneous schwannomas seen in NF1 and NF2 are not characteristic of SWN, and patients with this syndrome do not exhibit learning disabilities. SWN may be diagnosed by purely clinical criteria or by combined clinical and molecular criteria.

Diagnostic criteria for SWN:
Clinical diagnosis –
  • Two or more nonintradermal schwannomas, 1 pathologically confirmed schwannoma, and absence of bilateral vestibular schwannomas OR
  • One pathologically confirmed schwannoma, unilateral vestibular schwannoma, or intracranial meningioma and 1 affected first-degree relative with SWN
Combined molecular and clinical diagnosis –
  • Two or more pathologically confirmed schwannomas or meningiomas and 2 or more tumors with 22q loss of heterozygosity and 2 different somatic NF2 mutations and none of the exclusion criteria OR
  • One pathologically confirmed schwannoma or meningioma and a germline SMARCB1 or LZTR1 pathogenic variant
Exclusion criteria include any of the following –
  • A clinical diagnosis of NF2
  • A germline NF2 pathogenic variant
  • Schwannomas only within a radiation treatment field
Many individuals with NF lead long and healthy lives. Overall life expectancy may be decreased by as much as 15 years secondary to complications, however.


Q85.01 – Neurofibromatosis, type 1
Q85.02 – Neurofibromatosis, type 2
Q85.03 – Schwannomatosis

781641005 – Schwannomatosis
92503002 – Neurofibromatosis type 2
92824003 – Neurofibromatosis type 1

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

To perform a comparison, select diagnoses from the classic differential

Subscription Required

Best Tests

Subscription Required

Management Pearls

Subscription Required


Subscription Required


Subscription Required

Last Reviewed:01/24/2023
Last Updated:03/14/2024
Copyright © 2024 VisualDx®. All rights reserved.
Neurofibromatosis in Child
See also in: External and Internal Eye
A medical illustration showing key findings of Neurofibromatosis (Neurofibromatosis Type 1 (NF1)) : Lisch nodules, Axillary freckles
Clinical image of Neurofibromatosis - imageId=742400. Click to open in gallery.  caption: 'A close-up of pinkish and brownish papules and nodules (neurofibromas) and light brown patches (confetti and <span>café au lait </span> macules).'
A close-up of pinkish and brownish papules and nodules (neurofibromas) and light brown patches (confetti and café au lait macules).
Copyright © 2024 VisualDx®. All rights reserved.